Zoetis (ZTS) Q3 2024 Earnings Call Transcript
Welcome to the third quarter 2024 financial results conference call and webcast for Zoetis. Hosting the call today is Steve Frank, vice president of in
Q3 2024 Zoetis Inc Earnings Call
Linda Rhodes; Independent Director; Zoetis Inc Wetteny Joseph; Chief Financial Officer, Executive Vice President; Zoetis Inc Brandon Vazquez; Analyst; William Blair & Company L.L.C. David Westenberg; Analyst; Piper Sandler & Co. Navann Ty Dietschi; Analyst; BNP Paribas Exane
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
ZTS stock gains as third-quarter results beat both earnings and revenue estimates, driven by strong product sales. Management raises the 2024 outlook.
Zoetis Beats Q3 Earnings Expectations
Zoetis saw notable growth in both companion animal and livestock segments.
Zoetis Q3 Earnings Beat, Companion Animal Segment Growth Gives Confidence Into 2025: Analyst
Zoetis Inc's Q3 2024 results show a 16% EPS increase and an 11% revenue boost. The company raises its 2024 guidance, highlighting strong global growth in key segments.
Zoetis CEO Kristen Peck on Q3: Earnings beat driven by broad portfolio
Kristen Peck, Zoetis CEO, joins 'Money Movers' to discuss Zoetis' quarterly earnings results, what allowed the company to beat earnings expectations, and much more.
Zoetis: Q3 Earnings Snapshot
The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.46 per share. The animal health company posted revenue of $2.39 billion in the period, which also topped Street forecasts.
Zoetis Inc. Q3 Profit Increases, Beats Estimates
Zoetis Inc. (ZTS) revealed earnings for its third quarter that increased from last year and beat the Street estimates. The
Zoetis reports Q3 adjusted EPS $1.58, consensus $1.45
Reports Q3 revenue $2.39B, consensus $2.29B. “Building on the strong momentum from the first half of the year, we are proud to have ...
Zoetis raises annual forecasts on strong demand for pet treatments
Zoetis raised its annual profit and revenue forecasts on Monday on strong demand for its medicines and vaccines for animals.
Investing on MSN15h
Zoetis lifts full-year guidance amid strength at companion animal unit
Shares in Zoetis (NYSE: ZTS) edged higher in premarket US trading on Monday after the drugmaker reported better-than-anticipated third-quarter earnings and revenu ...
Barclays Sticks to Their Buy Rating for Zoetis (ZTS)
Barclays analyst Balaji Prasad maintained a Buy rating on Zoetis (ZTS – Research Report) today and set a price target of $242.00. The ...
Zoetis Inc. (ZTS) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ETCompany ParticipantsSteve Frank - VP of IRKristin Peck - ...